LabCorp® Obtains Exclusively License For New Epithelial Ovarian Cancer Diganostic Blood Test
Filed in archive Diagnostics, Methodologies and Instrumentation , Genomics, Proteomics and Bioinformatics , Patents and Intellectual Property Rights by ruth on February 27, 2006
Laboratory Corporation of America Holdings (LabCorp) acquired the rights to commercialize a diagnostic blood test for epithelial ovarian cancer (EOC) developed at Yale University.
"Ovarian cancer is one of the most difficult cancers to detect, especially in the earliest stages when it is more treatable," said Myla P. Lai-Goldman, M.D., Executive Vice President, Chief Scientific Officer and Medical Director of LabCorp. "LabCorp continues to dedicate resources to identifying and commercializing tests to help discriminate earlier between disease-free and cancer patients."
The test is an ELISA-based assay for known serum proteins associated with EOC, the results of which are evaluated using a score system. While preliminary Clinical trial
results have already shown that the technology is more sensitive and specific than currently available tests, Yale will continue to conduct additional clinical studies prior to commercialization.[Source: LabCorp®]
Permalink: LabCorp® Obtains Exclusively License For New Epithelial Ovarian Cancer Diganostic Blood Test
Tags:
ovarian cancer biotech blood test ovarian+cancer blood+test epithelial+ovarian
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/16400
